Men with prostate cancer can ask their oncologist and prescriber whether a GLP-1 medicine is appropriate for a separate condition such as type 2 diabetes or obesity. The FDA labels for Ozempic and Wegovy describe these uses and do not list prostate cancer as an indication [4] [5].
What the study found during hormone therapy
Our guide to GLP-1 and SGLT2 medicines explains why different comparators matter. In the prostate cancer study, the researchers created two separate matched comparisons among men with type 2 diabetes receiving androgen deprivation therapy: 659 people per group against DPP-4 inhibitors and 1,009 per group against SGLT2 inhibitors [1].
Compared with DPP-4 inhibitors, GLP-1 users had a lower hazard of death from any cause (hazard ratio 0.60, 95% confidence interval 0.46–0.79). Major kidney events and clotting events were also less common. The analysis did not detect a significant difference in major cardiovascular events (0.87, 0.63–1.12)[1].
Compared with SGLT2 inhibitors, the hazard ratio for death from any cause was 0.76 (0.59–0.99). The study did not detect significant differences in major cardiovascular events, major kidney events or clotting events in this comparison. Some of these estimates were based on relatively few events [1].
What studies of new diagnoses found
Our guide to GLP-1 use and new cancer diagnoses covers a separate question. A Danish study compared 14,206 men who started a GLP-1 with 21,756 who started basal insulin. The main hazard ratio for a new prostate cancer diagnosis was 0.91 (95% confidence interval 0.73–1.14). The analysis of continued use of the initial treatment gave 0.80 (0.64–1.01). Both intervals included 1 [2].
What researchers are testing next
The phase II IMPACT-ADT trial is designed to compare GLP-1 medicines and dietary interventions for cardiometabolic health during androgen deprivation therapy[3].